Cabozantinib

Search with Google Search with Bing

Information
Drug Name
Cabozantinib
Description
Entry(CIViC)
8
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
lung non-small cell carcinoma ROS1 CD74-ROS1 G2032R D Predictive Supports Sensitivity/Response Somatic 3 25351743 Detail
lung non-small cell carcinoma ROS1 CD74-ROS1 G2032R D Predictive Supports Sensitivity/Response Somatic 3 26372962 Detail
lung non-small cell carcinoma MET p.Asp1246Val (p.D1246V)
( ENST00000318493.11, ENST00000397752.8 ) MET p.Asp1246Val (p.D1246V)
( ENST00000318493.11, ENST00000397752.8 ) 		C Predictive Supports Sensitivity/Response Somatic 4 27694386 Detail
uveal melanoma GNA11 MUTATION GNA11 MUTATION B Predictive Supports Sensitivity/Response Somatic 3 28103611 Detail
lung non-small cell carcinoma RET UNKNOWN RET FUSION B Predictive Supports Sensitivity/Response Somatic 3 27825636 Detail
uveal melanoma GNAQ MUTATION GNAQ MUTATION B Predictive Supports Sensitivity/Response Somatic 2 28103611 Detail
colorectal cancer PIK3CA MUTATION PIK3CA MUTATION D Predictive Supports Sensitivity/Response Somatic 3 25242168 Detail
thyroid gland medullary carcinoma RET p.Met918Thr (p.M918T)
( ENST00000340058.6, ENST00000713926.1, ENST00000355710.8, ENST00000615310.5 ) RET p.Met918Thr (p.M918T)
( ENST00000340058.6, ENST00000355710.8, ENST00000615310.5, ENST00000713926.1 ) 		B Predictive Supports Sensitivity/Response Somatic 4 27525386 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Cabozantinib was assessed in the CD74-ROS1-mutant ... ROS1 ROS1 CD74-ROS1 G2032R Sensitivity true CIViC Evidence detail
Preclinical study analyzing the efficacy of dual R... ROS1 ROS1 CD74-ROS1 G2032R Sensitivity true CIViC Evidence detail
Case report of a patient with lung adenocarcinoma ... MET MET p.Asp1246Val (p.D1246V)
( ENST00000318493.11, ENST00000397752.8 ) MET p.Asp1246Val (p.D1246V)
( ENST00000318493.11, ENST00000397752.8 ) 		Sensitivity true CIViC Evidence detail
A randomized phase II trial assessing the efficacy... GNA11 GNA11 MUTATION GNA11 MUTATION Sensitivity true CIViC Evidence detail
RET rearrangements are found in 1-2% of non-small-... RET RET UNKNOWN RET FUSION Sensitivity true CIViC Evidence detail
Patients with metastatic melanoma (n=77; 48 cutane... GNAQ GNAQ MUTATION GNAQ MUTATION Sensitivity true CIViC Evidence detail
20 patient-derived colorectal cancer xenografts we... PIK3CA PIK3CA MUTATION PIK3CA MUTATION Sensitivity true CIViC Evidence detail
Cabozantinib significantly prolonged progression-f... RET RET p.Met918Thr (p.M918T)
( ENST00000340058.6, ENST00000713926.1, ENST00000355710.8, ENST00000615310.5 ) RET p.Met918Thr (p.M918T)
( ENST00000340058.6, ENST00000355710.8, ENST00000615310.5, ENST00000713926.1 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT04446117 Active, not recruiting Phase 3 Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC June 30, 2020 August 31, 2024
NCT04164979 Active, not recruiting Phase 2 Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma February 4, 2020 December 30, 2024
NCT04416646 Active, not recruiting Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma February 27, 2019 March 1, 2024
NCT04200443 Active, not recruiting Phase 2 Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma January 14, 2020 June 1, 2024
NCT04211337 Active, not recruiting Phase 3 A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer February 11, 2020 February 28, 2026
NCT04338269 Active, not recruiting Phase 3 A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment July 28, 2020 June 30, 2024
NCT01658878 Active, not recruiting Phase 1/Phase 2 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer October 30, 2012 June 28, 2024
NCT01979393 Active, not recruiting Phase 2 IRCI Gynae Sarcomas, High Grade Uterine Sarcoma February 2015 May 2024
NCT05663710 Active, not recruiting Phase 1/Phase 2 Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC June 30, 2023 October 30, 2027
NCT05249114 Active, not recruiting Phase 1 Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors December 28, 2022 December 1, 2026
NCT05200143 Active, not recruiting Phase 2 Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma June 8, 2022 June 2031
NCT02293980 Active, not recruiting Phase 1 A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) November 25, 2014 November 30, 2026
NCT02867592 Active, not recruiting Phase 2 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors May 18, 2017 September 21, 2024
NCT05100082 Active, not recruiting Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma November 17, 2021 November 30, 2025
NCT03141177 Active, not recruiting Phase 3 A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma August 22, 2017 April 17, 2024
NCT03149822 Active, not recruiting Phase 1/Phase 2 Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma September 28, 2017 December 31, 2025
NCT03170960 Active, not recruiting Phase 1/Phase 2 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors September 5, 2017 August 2024
NCT05052723 Active, not recruiting Phase 2 Cabozantinib and Pembrolizumab in Metastatic Pancreas January 4, 2022 December 19, 2024
NCT04963283 Active, not recruiting Phase 2 Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer June 23, 2021 February 9, 2026
NCT03468218 Active, not recruiting Phase 2 Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer September 18, 2018 January 5, 2025
NCT03534804 Active, not recruiting Phase 2 Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma September 18, 2018 May 31, 2025
NCT03539822 Active, not recruiting Phase 1/Phase 2 Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies October 22, 2018 November 30, 2027
NCT03541902 Active, not recruiting Phase 2 Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma May 15, 2018 July 31, 2025
NCT01441947 Active, not recruiting Phase 2 Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer October 2011 December 2023
NCT04868773 Active, not recruiting Phase 1 Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy July 16, 2021 February 2025
NCT03634540 Active, not recruiting Phase 2 A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) September 27, 2018 August 31, 2025
NCT03635892 Active, not recruiting Phase 2 A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma August 13, 2018 August 2024
NCT03667482 Active, not recruiting Phase 1 Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer September 7, 2018 September 2024
NCT03690388 Active, not recruiting Phase 3 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy October 5, 2018 December 2024
NCT03755791 Active, not recruiting Phase 3 Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy June 10, 2018 December 1, 2024
NCT03793166 Active, not recruiting Phase 3 Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study June 7, 2019 September 15, 2024
NCT03798626 Active, not recruiting Phase 1 Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers May 22, 2019 December 30, 2024
NCT04588051 Active, not recruiting Phase 2 Cabozantinib in Hepatocellular Carcinoma November 1, 2020 December 31, 2027
NCT04586231 Active, not recruiting Phase 3 A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) February 25, 2021 December 23, 2024
NCT06171854 Active, not recruiting Phase 2 caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer. September 1, 2019 December 31, 2024
NCT04551430 Active, not recruiting Phase 2 Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma January 5, 2021 June 1, 2030
NCT03937219 Active, not recruiting Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma June 25, 2019 March 2025
NCT03945773 Active, not recruiting Phase 2 Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors January 8, 2020 September 30, 2099
NCT04022343 Active, not recruiting Phase 2 Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer August 6, 2019 May 25, 2025
NCT04497038 Active, not recruiting Phase 1/Phase 2 Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy August 6, 2021 December 2026
NCT04477512 Active, not recruiting Phase 1 Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) February 19, 2021 March 31, 2026
NCT04471428 Active, not recruiting Phase 3 Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy October 1, 2020 October 31, 2024
NCT01683110 Approved for marketing Expanded Access of Cabozantinib in Medullary Thyroid Cancer
NCT01493869 Completed Phase 1 Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects September 2011 August 2014
NCT03200587 Completed Phase 1 Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) June 21, 2018 November 25, 2021
NCT04804813 Completed Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma March 29, 2021 March 31, 2024
NCT04510688 Completed Spanish Real-World Evidence Cabozantinib October 23, 2019 June 30, 2022
NCT03299946 Completed Phase 1 Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) May 14, 2018 October 1, 2021
NCT03316586 Completed Phase 2 A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer November 30, 2017 August 30, 2019
NCT03339219 Completed Phase 2 A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma December 13, 2017 August 25, 2020
NCT04197310 Completed Phase 2 Cabozantinib and Nivolumab for Carcinoid Tumors December 26, 2019 January 31, 2024
NCT03354884 Completed Phase 2 caBozantinib in cOllectiNg ductS Renal Cell cArcInoma January 12, 2018 November 19, 2020
NCT01599793 Completed Phase 2 Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer May 2012 December 2018
NCT04205799 Completed Phase 2 Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure January 15, 2020 January 15, 2023
NCT03370718 Completed Phase 2 Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma February 26, 2018 January 12, 2024
NCT01605227 Completed Phase 3 Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 July 2012 March 2015
NCT04316182 Completed Phase 2 Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION) July 31, 2020 February 22, 2023
NCT01630590 Completed Phase 2 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer January 8, 2014 April 6, 2021
NCT03428217 Completed Phase 2 CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma April 24, 2018 July 16, 2021
NCT00940225 Completed Phase 2 Study of Cabozantinib (XL184) in Adults With Advanced Malignancies September 2009 June 2014
NCT01347788 Completed Phase 1 Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer April 2011 May 2013
NCT04661852 Completed Phase 1 Cabozantinib With Topotecan-Cyclophosphamide December 23, 2020 October 24, 2022
NCT01663272 Completed Phase 1 A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer July 2012 March 1, 2017
NCT01683994 Completed Phase 1/Phase 2 Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer September 7, 2012 January 16, 2019
NCT01688999 Completed Phase 2 Cabozantinib for Advanced Urothelial Cancer September 11, 2012 September 14, 2020
NCT01588821 Completed Phase 2 Cabozantinib in Advanced Solid Malignancies June 2012 June 2019
NCT04134390 Completed Phase 2 Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study February 17, 2020 November 22, 2023
NCT04540705 Completed Phase 1 A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread September 11, 2020 January 18, 2024
NCT01574937 Completed Phase 1 XL-184+Abiraterone in Post-Chemo CRPC April 3, 2012 July 1, 2021
NCT01738438 Completed Phase 2 Cabozantinib for Metastatic Triple Negative BrCa February 2013 May 2015
NCT01755195 Completed Phase 2 Cabozantinib for Adults With Advanced Soft Tissue Sarcoma January 15, 2013 September 11, 2023
NCT01761773 Completed Phase 1 A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function December 2012 July 2014
NCT01834651 Completed Phase 2 A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases April 30, 2013 July 18, 2016
NCT01954745 Completed Phase 2 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma September 2013 June 2016
NCT01961765 Completed Phase 1 Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia November 2013 January 2017
NCT03468985 Completed Phase 2 Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer May 7, 2018 December 21, 2022
NCT04637204 Completed Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England November 24, 2020 December 11, 2020
NCT02008383 Completed Phase 1 Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer January 2014 August 29, 2018
NCT01582295 Completed Phase 1 XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease June 2012 November 2014
NCT02101736 Completed Phase 2 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults June 2014 February 16, 2022
NCT01466036 Completed Phase 2 Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors July 2012 December 2023
NCT02216578 Completed Phase 2 Ph II CABOGIST in GIST February 2, 2017 February 23, 2021
NCT02260531 Completed Phase 2 Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases November 2014 March 17, 2020
NCT03586973 Completed Phase 2 A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma August 6, 2018 June 29, 2021
NCT02592356 Completed N/A Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer November 16, 2015 March 1, 2024
NCT02795156 Completed Phase 2 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations September 28, 2016 August 17, 2022
NCT05859217 Not yet recruiting Phase 2 A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) December 2024 June 2028
NCT05241561 Not yet recruiting Phase 2 Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients June 2022 March 2027
NCT06341712 Not yet recruiting Phase 2 Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma June 13, 2024 June 15, 2028
NCT04412629 Recruiting Phase 2 Cabozantinib in High Grade Neuroendocrine Neoplasms November 24, 2020 March 31, 2026
NCT01639508 Recruiting Phase 2 Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity July 2012 July 2026
NCT02925234 Recruiting Phase 2 The Drug Rediscovery Protocol (DRUP Trial) August 2016 December 2027
NCT03611595 Recruiting Phase 1 Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors August 28, 2018 August 2024
NCT03768063 Recruiting Phase 3 A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study February 28, 2019 July 5, 2028
NCT03899155 Recruiting Phase 2 Pan Tumor Rollover Study August 9, 2019 August 25, 2029
NCT03899428 Recruiting Phase 2 Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC May 2, 2019 December 31, 2025
NCT03957551 Recruiting Phase 1/Phase 2 Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma August 27, 2019 December 31, 2026
NCT03967522 Recruiting Phase 2 Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases November 29, 2019 December 2024
NCT04116541 Recruiting Phase 2 A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. January 28, 2020 November 2026
NCT04204850 Recruiting Phase 2 Cabozantinib to Treat Recurrent Liver Cancer Post Transplant August 7, 2020 December 7, 2024
NCT04289779 Recruiting Phase 2 Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer May 21, 2020 May 2025
NCT04322955 Recruiting Phase 2 CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition June 22, 2020 February 2027
NCT04413123 Recruiting Phase 2 Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC November 5, 2020 December 20, 2025
NCT04472767 Recruiting Phase 2 Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma August 7, 2020 September 1, 2027
NCT04511455 Recruiting Phase 2 Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment December 8, 2020 December 31, 2025
NCT04524208 Recruiting Phase 2 A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 March 1, 2021 October 31, 2024
NCT04631744 Recruiting Phase 2 Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) March 3, 2021 May 31, 2025
NCT04767906 Recruiting Phase 2 Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors December 14, 2021 December 14, 2024
NCT04876456 Recruiting Phase 2 A Phase II Trial of Cabozantinib With Patients With Refractory GCTs June 10, 2021 December 2025
NCT05012371 Recruiting Phase 2 Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer February 16, 2022 October 25, 2025
NCT05038839 Recruiting Phase 1 Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors February 9, 2022 June 3, 2024
NCT05039281 Recruiting Phase 1/Phase 2 Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma September 23, 2022 December 31, 2025
NCT05048212 Recruiting Phase 2 A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases September 20, 2022 July 31, 2024
NCT05048901 Recruiting Phase 1/Phase 2 Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors September 17, 2021 December 31, 2025
NCT05127824 Recruiting Phase 2 Autologous Dendritic Cell Vaccine in Kidney Cancer July 6, 2023 December 2026
NCT05135975 Recruiting Phase 2 A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors October 18, 2021 December 2029
NCT05168163 Recruiting Phase 2 Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer May 27, 2022 December 31, 2026
NCT05188118 Recruiting Early Phase 1 Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma February 24, 2023 December 2025
NCT05263050 Recruiting Phase 2 Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma January 21, 2022 February 2027
NCT05327686 Recruiting Phase 2 Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study June 30, 2022 June 15, 2032
NCT05361720 Recruiting Phase 2 Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study December 1, 2022 July 1, 2026
NCT05425004 Recruiting Phase 2 Cabozantinib for Patients With Recurrent or Progressive Meningioma May 27, 2022 May 2028
NCT05502315 Recruiting Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer February 2, 2023 October 12, 2024
NCT05536141 Recruiting Phase 1 A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors October 26, 2022 January 2026
NCT05613894 Recruiting Phase 1 Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer June 26, 2023 May 1, 2028
NCT05660954 Recruiting Phase 2 Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. May 25, 2023 June 2025
NCT06026410 Recruiting Phase 1 KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors October 18, 2023 April 2027
NCT06132945 Recruiting Phase 1 A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain November 10, 2023 November 2027
NCT06156410 Recruiting Phase 1 Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma October 24, 2023 November 2028
NCT06364631 Recruiting Phase 3 CARE1 Pragmatic Clinical Trial April 12, 2024 May 5, 2032
NCT05836571 Suspended Phase 2 Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma October 25, 2023 May 15, 2026
NCT05019703 Suspended Phase 2 Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study April 25, 2023 December 31, 2027
NCT04091750 Suspended Phase 2 Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma March 2, 2020 May 2024
NCT04173338 Terminated Phase 1 Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma January 23, 2020 March 28, 2022
NCT01428219 Terminated Phase 2 Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone February 2012 September 2015
NCT06377722 Terminated Phase 2 Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer November 1, 2018 August 9, 2022
NCT03201250 Terminated Phase 1/Phase 2 Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma February 21, 2018 April 12, 2021
NCT02885324 Terminated Phase 2 Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children May 18, 2017 August 25, 2020
NCT04066595 Terminated Phase 2 Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. February 10, 2020 July 1, 2021
NCT03964337 Terminated Phase 2 Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer March 17, 2020 June 4, 2021
NCT01995058 Terminated Phase 2 Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer December 2013 November 2014
NCT03878524 Terminated Phase 1 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial April 1, 2020 December 10, 2020
NCT01703065 Terminated Phase 2 Cabozantinib in Men With Castration-Resistant Prostate Cancer June 18, 2013 September 18, 2015
NCT03729297 Terminated Phase 2 Cabozantinib in Advanced Salivary Gland Cancer Patients September 5, 2018 November 6, 2019
NCT03729245 Terminated Phase 3 A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) December 18, 2018 October 19, 2022
NCT01522443 Terminated Phase 3 Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer March 2012 January 13, 2015
NCT03630120 Terminated Phase 2 Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer August 6, 2018 December 5, 2019
NCT02132598 Terminated Phase 2 Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases December 2015 August 9, 2019
NCT02036476 Terminated Phase 2 Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma February 2014 July 2016
NCT03239015 Unknown status Phase 2 Efficacy and Safety of Precision Therapy in Refractory Tumor January 1, 2017 December 31, 2023
NCT05265988 Unknown status Phase 2 Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib October 29, 2021 October 29, 2023
NCT03943602 Unknown status Phase 2 Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen) August 1, 2019 September 1, 2022
NCT03911193 Unknown status Phase 2 CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation September 21, 2018 September 2020
NCT03824691 Unknown status Phase 2 hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" September 25, 2019 February 2023
NCT04454762 Unknown status Phase 2 A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function July 22, 2020 February 1, 2024
NCT03685448 Unknown status Phase 2 ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) April 11, 2019 April 30, 2024
NCT04427787 Unknown status Phase 2 A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET June 20, 2020 November 2023
NCT02041260 Unknown status Phase 2 A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting January 2014 May 2022
NCT04151563 Withdrawn Phase 1/Phase 2 A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy April 15, 2021 May 13, 2026
NCT05039736 Withdrawn Phase 2 A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy February 24, 2023 May 3, 2023
NCT04149275 Withdrawn Phase 2 Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma February 2021 February 2021
NCT04760288 Withdrawn Phase 3 A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). November 30, 2023 April 12, 2035